Friday 6 November 2026
Export ANIP’s income statement to Excel — free account
ANI Pharmaceuticals, Inc.
ANIP Healthcare Drug Manufacturers Specialty & Generic
ANI Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $883.4 million, up 43.8% from fiscal 2024.
- Revenue
- +27.6%
- EPS
- +39.2%
- Free cash flow
- +85.5%
- Total debt
- −2.11%
Quarter to September 2026, against a year earlier
67.14
2.48
−3.56%
Follow ANIP
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
7 | 8 | 7 | 7 |
| 16.34% | 18.63% | 20.88% | 20.45% | ||
| 5.66% | 6.73% | 7.61% | 7.85% | ||
ROIC |
8.05% | 9.10% | 11.30% | 12.88% | |
Return on Tangible Assets |
14.36% | 15.90% | 17.56% | 17.82% | |
Average Days of Receivables |
116.14 | 100.93 | 102.40 | 106.71 | |
Free Cash Flow per Share |
7.53 | 8.74 | 7.92 | 9.68 | |
Free Cash Flow |
150.90 | 182.81 | 167.52 | 205.32 | |
Capital Expenditures |
(34.32) | (25.80) | (21.94) | (23.87) | |
| Other line items | |||||
Cash ROIC |
10.39% | 12.17% | 10.58% | 12.22% | |
Accounts Receivable Turnover |
3.51 | 3.88 | 3.91 | 3.74 | |
Accounts Payable Turnover |
6.31 | 5.90 | 6.03 | 5.62 | |
Inventory Turnover |
2.44 | 2.58 | 2.75 | 2.87 | |
Average Days of Payables |
66.93 | 70.30 | 69.56 | 66.98 | |
Days of Inventory on Hand |
153.00 | 144.71 | 134.87 | 122.77 | |
Tax Rate |
(0.18) | (0.21) | (0.24) | (0.26) | |
Research and Development Expense of Revenue |
5.85% | 5.60% | 5.10% | 4.86% | |
Selling, General and Administrative Expense of Revenue |
35.97% | 34.09% | 33.19% | 32.94% | |
Share Based Compensation of Revenue |
4.29% | 4.25% | 4.20% | 4.13% | |
Interest Coverage |
5.54 | 6.75 | 9.09 | 11.19 | |
Operating CF/Net income |
2.40 | 2.28 | 1.75 | 1.96 | |
Depreciation/Fixed assets |
1.46 | 1.33 | 1.17 | 0.00 | |
Capex/Depreciation |
(0.38) | (0.29) | (0.26) | 0.00 | |
Revenue per Share |
44.05 | 44.17 | 46.24 | 49.09 | |
Operating CF per Share |
9.24 | 9.97 | 8.95 | 10.81 | |
Capex per Share |
(1.71) | (1.23) | (1.04) | (1.13) | |
Capex to Sales |
0.04 | 0.03 | 0.02 | 0.02 |
Columns are period end dates · fundamentals updated 6 Nov 2026